Low-dose combination blood pressure pharmacotherapy to improve treatment effectiveness, safety, and efficiency

Mark D. Huffman; Gbenga Ogedegbe; Marc Jaffe

doi:10.1001/jama.2018.10649

Low-dose combination blood pressure pharmacotherapy to improve treatment effectiveness, safety, and efficiency

Mark D. Huffman
, Gbenga Ogedegbe
, Marc Jaffe

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	552-554
Number of pages	3
Journal	JAMA - Journal of the American Medical Association
Volume	320
Issue number	6
DOIs	https://doi.org/10.1001/jama.2018.10649
State	Published - Aug 14 2018

Access to Document

10.1001/jama.2018.10649

Cite this

@article{841abb367edf4f65a08b1b330684f1f0,

title = "Low-dose combination blood pressure pharmacotherapy to improve treatment effectiveness, safety, and efficiency",

author = "Huffman, \{Mark D.\} and Gbenga Ogedegbe and Marc Jaffe",

note = "Funding Information: completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Huffman reported receiving funding from the World Heart Federation to serve as its senior program advisor for the emerging leaders program, which is funded through unrestricted educational grants from Boehringer Ingelheim and Novartis with previous support from Bupa and AstraZeneca; funding support from the American Heart Association, Verily, and AstraZeneca; and being co-leader of a clinical trial evaluating the effects of quarter-dose, 4-drug blood pressure–lowering combination therapy, which is sponsored by the National Heart, Lung, and Blood Institute. No other disclosures were reported.",

year = "2018",

month = aug,

day = "14",

doi = "10.1001/jama.2018.10649",

language = "English",

volume = "320",

pages = "552--554",

journal = "JAMA - Journal of the American Medical Association",

issn = "0098-7484",

number = "6",

}

TY - JOUR

T1 - Low-dose combination blood pressure pharmacotherapy to improve treatment effectiveness, safety, and efficiency

AU - Huffman, Mark D.

AU - Ogedegbe, Gbenga

AU - Jaffe, Marc

N1 - Funding Information: completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Huffman reported receiving funding from the World Heart Federation to serve as its senior program advisor for the emerging leaders program, which is funded through unrestricted educational grants from Boehringer Ingelheim and Novartis with previous support from Bupa and AstraZeneca; funding support from the American Heart Association, Verily, and AstraZeneca; and being co-leader of a clinical trial evaluating the effects of quarter-dose, 4-drug blood pressure–lowering combination therapy, which is sponsored by the National Heart, Lung, and Blood Institute. No other disclosures were reported.

PY - 2018/8/14

Y1 - 2018/8/14

UR - https://www.scopus.com/pages/publications/85051627817

U2 - 10.1001/jama.2018.10649

DO - 10.1001/jama.2018.10649

M3 - Editorial

C2 - 30120460

AN - SCOPUS:85051627817

SN - 0098-7484

VL - 320

SP - 552

EP - 554

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

IS - 6

ER -

Low-dose combination blood pressure pharmacotherapy to improve treatment effectiveness, safety, and efficiency

Access to Document

Other files and links

Cite this